AAV vectors are a relatively new system for gene therapy.
The Company believes that AAV vectors can be used to deliver genes for the treatment of hemophilia, Gaucher disease, Parkinson's disease and beta-thalassemia. The products are designed for in vivo administration to achieve the production of therapeutic proteins within the body. Results reflect the absence of grant and other revenues in the current quarter, and higher personnel and premises expenses. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved.